News

This delisting covers all its listed securities, including Units, Class A Ordinary Shares, and Warrants. This significant move marks a major adjustment in VCIC's capital operation strategy. After delisting, the related securities will no longer be publicly traded on Nasdaq. Such actions by a company usually involve complex compliance considerations and strategic planning; the specific reasons and subsequent arrangements are yet to be further disclosed.

The extension of this agreement marks the company's forward-looking approach to long-term financial planning. By extending the validity of its credit facilities by five more years, the company not only strengthens the security of its liquidity, but also reserves ample flexibility for future strategic investments and operational expansion. The renewal of the credit agreement often reflects the financial institution's recognition of the company's creditworthiness. In the context of current interest rate fluctuations, securing long-term credit resources helps to mitigate refinancing risks and provides stable support for ongoing infrastructure upgrades and green energy transition projects.

This rating adjustment reflects analysts' prudent assessment of the company's short-term valuation and growth prospects. Although the rating has been lowered, the "outperform" rating still indicates the institution's optimistic attitude toward Boston Scientific's medium and long-term performance. The adjustment of the target price may be based on a comprehensive consideration of the overall environment of the medical device industry, the company's recent financial performance, and the market competition situation. The market will closely monitor Boston Scientific's performance in upcoming quarters to verify the rationality of this rating adjustment.